Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815450 · ClinicalTrials.gov registry record · Phase 2
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
A Phase 2 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 369
- Enrollment target
NCT01815450 is a Phase 2 study that has completed, run by Braintree Laboratories. The registered enrollment target is 369 participants.
The verdict
NCT01815450, a Phase 2 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 369 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
Interventions
- DRUG Placebo
- DRUG BLI1100
- DRUG BLI1100 - modified formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815450
The ClinicalTrials.gov registry entry for NCT01815450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01815450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01815450 about?
NCT01815450 is a clinical study titled "BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris". The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
What is the current status of trial NCT01815450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 369 participants. The study started on 2013-02.
What interventions are being tested in trial NCT01815450?
The interventions under investigation include: Placebo (DRUG), BLI1100 (DRUG), BLI1100 - modified formulation (DRUG).
Who is sponsoring clinical trial NCT01815450?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.